Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder.

Trial Profile

Quetiapine XR Monotherapy or Adjunctive Therapy to Antidepressants in the Treatment of Major Depressive Disorder With Comorbid Generalized Anxiety Disorder.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2016

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Generalised anxiety disorder; Major depressive disorder
  • Focus Registrational; Therapeutic Use
  • Most Recent Events

    • 28 May 2013 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Actual patients number (33) added as reported by ClinicalTrials.gov.
    • 13 Dec 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top